Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Commentary|Articles|July 14, 2026
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Advertisement
Advertisement
Recent months have been filled with breast cancer research highlights from major conferences and more. Need a refresher? We’ve got you covered with this recap of pivotal phase 3 data announcements and highlights, many of which have already changed the breast cancer treatment paradigm across disease subtypes.
Related to this article
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA-approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and hypercalcemia of malignancy.
The sNDA for elinzanetant seeks FDA approval for moderate to severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement